“What makes I-O transformative?” Innovative approaches in patient selection, use of combinations, and sequencing of therapies lead to more patients benefitting from I-O therapy, expanding its potential impact and this also makes it more promising- from the basics of immunotherapies to the latest research results. The rapid development of immuno-oncology (I-O) therapies has transformed the treatment landscape and brightened the long-term outlook for many patients with advanced cancer.
Following the exceptional success of 2 editions in the USA and 4 editions in the UK, MarketsandMarkets is proud to announce the 3rd Annual Next Gen Immuno-Oncology Congress to be held on 25th and 26th June 2020 in Boston, USA. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, monoclonal antibody & Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, brain-storming on cancer biomarker and vaccine research, collaborating on pre-clinical and translational immune-oncology developments, and personalized cancer immunotherapy.
For any queries regarding the hotel booking please write to us at firstname.lastname@example.org
Hotel Booking Link
You will receive a link to book your accommodation via email once you are fully registered. (Please note that we do not authorize any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than us regarding your accommodation requirements for this event, please let us know immediately on email@example.com